Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6086918 | 0.82 | PTPN11 (0.43) | PTPN11CYP1A2 | |
| SCHEMBL5310259 | 0.81 | CYP1A2 (0.41) | PTPN11CYP1A2 | |
| SCHEMBL6090330 | 0.81 | OPRK1 (0.49) | HTR2COPRM1OPRD1OPRK1 | |
| SCHEMBL1671403 | 0.81 | DPP4 (0.47) | PTPN11CYP1A2 | |
| SCHEMBL6086970 | 0.78 | CRBN (0.40) | CRBNDDB1OPRM1OPRD1OPRK1 | |
| SCHEMBL6088673 | 0.77 | PTPN11 (0.40) | PTPN11CYP1A2 | |
| SCHEMBL5363229 | 0.77 | OPRK1 (0.45) | HTR2COPRM1OPRD1OPRK1 | |
| SCHEMBL6086561 | 0.75 | TSHR (0.40) | PTPN11OPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL6088414 | 0.75 | CYP3A4 (0.40) | PTPN11CYP1A2 | |
| SCHEMBL6094472 | 0.74 | CALCA (0.42) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115601-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050261322-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261322-A1 | HIV integrase inhibitors | TYMP, PAICS, TYMS | CRBN 4140/4885DDB1 776/4885PTPN11 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.